# Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Source: https://onco.cc/trials/nct06726161/  
OnCo record `nct06726161` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RYZ801 in hepatocellular carcinoma, run by RayzeBio, Inc., now recruiting.

## Summary

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC is a phase 1/2 interventional study registered as NCT06726161 by RayzeBio, Inc., with 590 participants planned, started 2025-09-05 and due to reach its primary completion in 2030-06. Interventions recorded: RYZ801.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06726161
- Phase: 1/2
- Setting: Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)
- Sponsor: RayzeBio, Inc.
- Enrolled: 590

## Sources

- ClinicalTrials.gov NCT06726161: https://clinicaltrials.gov/study/NCT06726161

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [RayzeBio (BMS)](https://onco.cc/companies/rayzebio/)

---
JSON: https://onco.cc/api/v1/entities/nct06726161.json